The Medicines Company (NASDAQ:MDCO) surged +2.30% and closed the trade at $ 38.75. The company recorded a trading capacity of 1.35 million shares above its three months average daily volume of 901.96 thousand shares. During the last trade, shares reached to high price of $38.80 and touched the low price of $37.06. The stock’s 50-day moving average is noted at $38.23 and its 200-day moving average is stands at $35.48.
Additionally, the companyhas EPS of -3.22. The company has market capitalization of $2.70B.
Currently The Medicines Company (MDCO) captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “9″ Analysts”. “0” rated “Sell” for the company. “1” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $50.70 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $65.00 however minimum price target advised by analysts is $43.00. The Median price target for the stock is measured at $51.00.
Presently, Analysts decided consensus EPS estimate of $-1.31 for present quarter and one month ago projected EPS estimate was at $-1.31. If we take a look at back 3 month ago, consensus EPS estimate was $-1.17.
A current consensus EPS estimate for next quarter is at $-1.33 and 3 month ago EPS forecast was $-1.15. Have a look at back 1 month ago, consensus EPS forecast was seen at $-1.33.
For current fiscal year, most recent EPS estimate is set at $-1.38 based on Analyst consensus and three month ago consensus EPS opinions was at $-4.74. During period one month ago, consensus EPS forecast was decided at $-1.53.
A current consensus EPS projection for next fiscal year is observed at $-4.31 and one month ago consensus EPS forecast was at $-4.43. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-3.83 by analysts.
One Month ago, the stock has gained consensus mean rating of Buy based on the analysis of brokerage analyst firms polled. 9 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 1 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 9 said a “Buy Rating” and 0 announced “Overweight Rating”. 1 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.